Remove Heart Failure Remove Hospital Remove Quality of Life
article thumbnail

Allina Health’s Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

DAIC

A team at Allina Health’s Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair.

article thumbnail

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

DAIC

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111
article thumbnail

Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care

DAIC

Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices.

article thumbnail

M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation

HCPLive

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

article thumbnail

Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

article thumbnail

RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).